Bellicum Pharmaceuticals (BLCM) Given Media Impact Rating of 0.18
News coverage about Bellicum Pharmaceuticals (NASDAQ:BLCM) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Stock Price Performance Review for Bellicum Pharmaceuticals, Inc … – Jonesboro Recorder (jonesbororecorder.com)
- Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer – GlobeNewswire (press release) (globenewswire.com)
- Parkwood LLC Sells 1031 Shares of Leucadia National Corporation (NYSE:LUK) (campdesrecrues.com)
- Checking Indicator Levels for Bellicum Pharmaceuticals Inc (BLCM) – Hayden Business Journal (haydenbusinessjournal.com)
Bellicum Pharmaceuticals (BLCM) traded up 5.71% during midday trading on Friday, reaching $10.74. 458,953 shares of the company’s stock were exchanged. The firm’s market capitalization is $355.53 million. The stock’s 50 day moving average is $11.88 and its 200 day moving average is $12.49. Bellicum Pharmaceuticals has a 52 week low of $9.71 and a 52 week high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by $0.10. The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.09 million. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 63.42%. Bellicum Pharmaceuticals’s quarterly revenue was up 39.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.56) earnings per share. On average, analysts expect that Bellicum Pharmaceuticals will post ($2.84) EPS for the current fiscal year.
A number of research analysts have weighed in on the stock. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Cantor Fitzgerald set a $32.00 price objective on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Wells Fargo & Company restated an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Ladenburg Thalmann Financial Services set a $31.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Finally, Jefferies Group LLC dropped their price objective on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.43.
In related news, CFO Alan A. Musso sold 6,311 shares of Bellicum Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $12.24, for a total value of $77,246.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $11.54, for a total value of $115,400.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,571 shares of company stock worth $367,295. Corporate insiders own 23.30% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.